SCHEMBL3447602

SCHEMBL3447602

C[Si](C)(C)/N=C/c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MEN1 O00255 6/20 0.45
KMT2A Q03164 6/20 0.45
ALDH1A1 P00352 4/20 0.42
CYP2A6 P11509 1/20 0.42
NOX1 Q9Y5S8 1/20 0.41
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 1/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 3/20 0.40
GRIN2D O15399 2/20 0.40
GRIN3B O60391 2/20 0.40
GRIN1 Q05586 2/20 0.40
GRIN2A Q12879 2/20 0.40
GRIN2B Q13224 2/20 0.40
GRIN2C Q14957 2/20 0.40
GRIN3A Q8TCU5 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2488433 1.00 LMNA (0.52) LMNAL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL9322281 0.78 ALDH1A1 (0.67) LMNAL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL31668429 0.76 NPC1 (0.44) LMNAMEN1KMT2AALDH1A1RAB9A
SCHEMBL8240652 0.74 NPSR1 (0.57) LMNAL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL8507909 0.73 LMNA (0.50) LMNAL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL2748317 0.73 LMNA (0.50) LMNAL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL7731054 0.73 ALDH1A1 (0.54) LMNAL3MBTL1KMT2AALDH1A1CYP2A6
SCHEMBL9336979 0.73 MAOB (0.52) LMNAL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL24715428 0.70 LMNA (0.60) LMNAL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL1017490 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6703446-B2 POLYMERS HAVING DIFFERENT FUNCTIONALITIES AT OPPOSITE ENDS OF THE POLYMER CHAIN; CAN BE COPOLYMERIZED WITH OTHER MONOMERS TO PROVIDE NOVEL COPOLYMERS POSSESSING A WIDE RANGE OF PHYSICAL PROPERTIES FMC CORPORATION, LITHIUM DIVISION 2004-03-09 US claimed
US-6699939-B2 POLYMERS HAVING DIFFERENT FUNCTIONALITIES AT OPPOSITE ENDS OF THE POLYMER CHAIN; CAN BE COPOLYMERIZED WITH OTHER MONOMERS TO PROVIDE NOVEL COPOLYMERS POSSESSING A WIDE RANGE OF PHYSICAL PROPERTIES FMC CORPORATION, LITHIUM DIVISION 2004-03-02 US claimed
US-20030032746-A1 Hetero-telechelic polymers and processes for making same FMC CORPORATION 2003-02-13 US claimed
US-20030032745-A1 Hetero-telechelic polymers and processes for making same SCHWINDEMAN JAMES A (US) 2003-02-13 US claimed
US-20030013827-A1 Hetero-telechelic polymers and processes for making same FMC CORPORATION 2003-01-16 US claimed
EP-0842199-B1 HETERO-TELECHELIC POLYMERS AND PROCESSES FOR MAKING SAME FMC CORP (US) 2002-04-03 EP claimed
US-6221991-B1 STAR POLYMER FMC CORPORATION 2001-04-24 US claimed
US-6197891-B1 Functionalized chain extended initiators for anionic polymerization FMC CORPORATION 2001-03-06 US claimed
US-6160054-A Hetero-telechelic polymers and processes for making same FMC CORPORATION (US) 2000-12-12 US claimed
US-5849847-A Telechelic polystyrene/polyethylene copolymers and processes for making same FMC CORPORATION (US) 1998-12-15 US claimed
WO-1997023520-A1 FUNCTIONALIZED CHAIN EXTENDED INITIATORS FOR ANIONIC POLYMERIZATION FMC CORPORATION (US) 1997-07-03 WO claimed
US-20130331369-A1 3-Spirocyclic Piperidine Derivatives as Ghrelin Receptor Agonists NOVARTIS AG (CH) 2013-12-12 US disclosed
US-20130296358-A1 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS NOVARTIS PHARMACEUTICALS UK LIMITED (GB) 2013-11-07 US disclosed
US-8546416-B2 3-spirocyclic piperidine derivatives as ghrelin receptor agonists NOVARTIS AG (CH) 2013-10-01 US disclosed
EP-1948669-B1 NEW METHODS FOR THE PREPARATION OF TAXANES USING CHIRAL AUXILIARIES ACCORD HEALTHCARE INC (CA) 2013-07-10 EP disclosed
US-5115035-A Modified block copolymer of conjugated diene and vinylaromatic and a tackifier resin ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1992-05-19 US disclosed
EP-0473206-A2 Compositions containing a terminal-modified block copolymer Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1992-03-04 EP disclosed
EP-0442576-A1 Synthesis of cis-beta-lactams with the aid of an alkali metal compound RIJKSUNIVERSITEIT UTRECHT (NL) 1991-08-21 EP disclosed
US-4791174-A VINYLAROMATIC/DIENE LIVING POLYMERS MODIFIED BY IMINE, HYDRAZONE OR AZINE COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 1988-12-13 US disclosed
EP-0245505-A1 TERMINAL-MODIFIED BLOCK COPOLYMER AND COMPOSITION CONTAINING SAID COPOLYMER Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1987-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331369-A1 3-Spirocyclic Piperidine Derivatives as Ghrelin Receptor Agonists GIPR, GHSR, GLP1R LMNA 3036/4885L3MBTL1 4760/4885MEN1 2501/4885
US-20130296358-A1 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS GIPR, GHSR, GLP1R LMNA 3036/4885L3MBTL1 4760/4885MEN1 2501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.